+

WO1992002530A1 - Hexa-n-(o-hydroxybenzyl) neomycine b destinee a l'inhibition des retrovirus humains et au traitement du sida - Google Patents

Hexa-n-(o-hydroxybenzyl) neomycine b destinee a l'inhibition des retrovirus humains et au traitement du sida Download PDF

Info

Publication number
WO1992002530A1
WO1992002530A1 PCT/US1991/004849 US9104849W WO9202530A1 WO 1992002530 A1 WO1992002530 A1 WO 1992002530A1 US 9104849 W US9104849 W US 9104849W WO 9202530 A1 WO9202530 A1 WO 9202530A1
Authority
WO
WIPO (PCT)
Prior art keywords
human
neomycin
hydroxybenzyl
poly
infected
Prior art date
Application number
PCT/US1991/004849
Other languages
English (en)
Inventor
William Gary Tarpley
Roman P. Holysz
Original Assignee
The Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Upjohn Company filed Critical The Upjohn Company
Publication of WO1992002530A1 publication Critical patent/WO1992002530A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/228—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
    • C07H15/232—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with at least three saccharide radicals in the molecule, e.g. lividomycin, neomycin, paromomycin

Definitions

  • Hexa-N-(o-hy ⁇ roxybenzyl )Neomyci B for inhibiting human retroviruses and for the treatment of AIDS
  • This invention relates to N-poly-(o-hydroxybenzyl) Neomycin B or salts and/or hydrates thereof, as a drug to treat a human cell system, including a human patient, possibly infected with a human retrovirus (HRV) to prevent or retard the further replication of the HRV in that human system or patient.
  • HRV human retrovirus
  • AZT zidovudine
  • U.S. Patent 4,724,232 claims a method of treating humans having acquired immunodeficiency syndrome utilizing 3'-azido-3'-deoxy-thymidine (azidothymidine, AZT).
  • European Patent Application 88306456.0 Publication No. 0 0300 687; 25.01.89 Bulletin
  • 89/04 describes a method of inhibiting human immunodeficiency virus utilizing a therapeutically effective amount of an antiviral agent to attack the first splice acceptor site of tat m gene of HIV.
  • OMPs Oligodeoxyyribonucleosidemethylphosphonates
  • This invention is a method for treating a human infected with one or more than one strain of a human immunodeficiency virus which comprises administering an effective amount of a N- poly-(o-hydroxybenzyl) Neomycin B, or salts and/or hydrates thereof, to the infected human.
  • a N- poly-(o-hydroxybenzyl) Neomycin B or salts and/or hydrates thereof
  • alkali metal salt forms of N-poly-(o-hydroxybenzyl) Neomycin B include the sodium, potassium and lithium salts thereof.
  • human retrovirus includes human immunodeficiency virus type I, human immunodeficiency virus type II, or strains thereof, as well as human T cell leukemia virus 1 and
  • HTLV-1 and HTLV-2 strains apparent to one skilled in the art, which belong to the same viral families and which create similar physiological effects in humans as various human retroviruses
  • Patients to be treated would be those individuals: 1) infected with one or more than on strain of a human retrovirus as determined by the presence of either measurable viral antibody antigen in the serum and 2) having either a symptomatic AIDS defining infection such as disseminated histoplasmosis, ii) isopsoriasis, iii) bronchial and pulmonary candidiasis includin pneumocystic pneumonia iv) non-Hodgkin's lymphoma or v) Kaposi's sarcoma and being less tha
  • Treatment would consist of maintaining an inhibitory level of the compound use according to this invention in the patient at all times and would continue until the occurrence o a second symptomatic AIDS defining infection indicates alternate therapy is needed.
  • N-poly-(o-hydroxybenzyI) Neomycin B is illustrated in Chart I where R is -(2-hydroxy)phenyl.
  • th dosage forms include oral formulations, such as tablets or capsules, or parenteral formulations, such as sterile solutions.
  • an effective amount is from about 1 to 100 mg per kg per day.
  • a typical unit dose for a 70 kg human would be from about 50 mg to 1000 mg, preferably 200 mg to 1000 mg taken one to four times per day.
  • Either solid or fluid dosage forms can be prepared for oral administration.
  • Solid compositions are prepared by mixing the compounds used to practice the method claimed in this invention with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methyl cellulose, or functionally similar pharmaceutics diluents and carriers.
  • Capsules are prepared by mixing the compounds used to practice the method claimed in this invention with an inert pharmaceutical diluent and placing the mixture into an appropriately sized hard gelatin capsule.
  • Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compounds used to practice the method claimed in this invention with an acceptable inert oil such as vegetable oil or light liquid petrolatum.
  • Syrups are prepared by dissolving the compounds used to practice the method claimed in this invention in an aqueous vehicle and adding sugar, aromatic flavoring agents and preserva- tives.
  • Elixirs are prepared using a hydroalcoholic vehicle such as ethanol, suitable sweeteners such as sugar or saccharin and an aromatic flavoring agent.
  • Suspensions are prepared with an aqueous vehicle and a suspending agent such as acacia, tragacanth, or methyl cellulose.
  • parenteral solutions are prepared by dissolving the compounds used to practice the method claimed in this invention in water and filter sterilizing the solution before placing in a suitable sealable vial or ampule.
  • Parenteral suspensions are prepared in substantially the same way except a sterile suspension vehicle is used and the compounds used to practice the method claimed in this invention are sterilized with ethylene oxide or suitable gas before it is suspended in the vehicle.
  • Patients to be treated would be those individuals: 1) infected with one or more than one strain of a human immunodeficiency virus as determined by the presence of either measurable viral antibody or antigen in the serum and 2) having either a symptomatic AIDS defining infection such as i) disseminated histoplasmosis, ii) isoporiasis, iii) bronchial and pulmonary candidiasis including pneumocystis pneumonia, iv) non-Hodgkin's lymphoma, or v) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4 lymphocyte count of less than 200/mm 3 in the peripheral blood.
  • Treatment would consist of maintaining an inhibitory level of the compounds of this invention in the patient at all times and would continue until the occurrence of a second symptomatic AIDS defining infection indicates alternate therapy is needed.
  • Preparation 1 Preparation of N-poly-(o-hydroxybenzyl) Neomycin B Part A:
  • Neomycin B free base 12.33 g. (20mM) of Neomycin B free base is dissolved in 25 ml. of water. The solution is diluted with 50 ml of methanol. The resulting solution is mixed with an aqueous methanol solution of salicylaldehyde (SAL; salicylic aldehyde; 2-hydroxybenzaldehyde) consisting of 17.1 g. (140 mM) of the SAL, 100 ml methanol and 200 ml water). The resulting solution is heated to boiling, then allowed to stand at room temperature for SAL, SAL, 100 ml methanol and 200 ml water). The resulting solution is heated to boiling, then allowed to stand at room temperature for
  • the product of Part A is dissolved in 200 ml methanol and hydrogenated at roo temperature at 50 psi initial pressure for 24 hours with 1.0 g of PtO 2 (Adams' catalyst). T pressure drop is 7.0 psi per 100 mM.
  • the product is filtered through diatomaceous earth (Celit and the filtrate concentrated jn vacuo to about 50 ml and resulting concentrate added slowly to 30 ml of ether.
  • the resulting mixture is refrigerated overnight, filtered/decanted and the solid produ - dried initially at room temperature in vacuo for several days and finally overnight at 50° C. in vacuum oven to yield 9.5 g of N-poly-(o-hydroxybenzyl) Neomycin B.
  • N-poly-(o-hydroxybenzyl) Neomycin B 50 gm
  • N-poly-(o-hydroxybenzyl) Neomycin B 50 mg
  • N-poly-(o-hydroxybenzyl) Neomycin B is sterilized, added to the sterile water, filled into sterile containers and sealed.
  • N-poly-(o-hydroxybenzyl) Neomycin B to practice the method claimed in this invention to inhibit HIV-1 tat mediated transactivation, enzyme essential for human immunodeficiency virus replication.
  • HIV contains various genes, including "tat” which encodes a trans-activator (TAT) that functions in the infected cell by increasing the levels of steady-state viral mRNA as well as the translational utilization of this mRNA. TAT is both essential for HIV replication and not structurally related to any normal cellular protein.
  • TAT trans-activator
  • "A Rapid, Quantitative Bioassay Based on the Human Immunodeficiency Virus Trans-Activator” is described in AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 5, Number 5, 1989, pp 507-516. The results (% Inhibition in sCD4 levels) in Table I.
  • the anti-HIV utility of this invention is further demonstrated by determining the levels of HIV p24 and HIV RNA in culture supematants of human peripheral blood lymphocytes (PBLs) 3 and 4 days after HIV infection.
  • the HIV infectivity experiments were conducted in primary cultures of (PBLs) with HTLV-IIIB. Cultures were infected in triplicate with HIV, Compound 1 added, and 3 to 4 days after infection the levels of HIV p24 synthesized and released were quantified by an enzyme-linked immunosorbent assay (ELISA) [R. Maiolini and R. Masseyeff, J. Immunol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La N-poly-(o-hydroxybenzyl) Néomycine B, ou ses sels et/ou hydrates, peut servir au traitement des personnes infectées par une ou plusieurs souches d'un virus de l'immunodéficience humaine.
PCT/US1991/004849 1990-07-30 1991-07-16 Hexa-n-(o-hydroxybenzyl) neomycine b destinee a l'inhibition des retrovirus humains et au traitement du sida WO1992002530A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55985190A 1990-07-30 1990-07-30
US559,851 1990-07-30

Publications (1)

Publication Number Publication Date
WO1992002530A1 true WO1992002530A1 (fr) 1992-02-20

Family

ID=24235298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004849 WO1992002530A1 (fr) 1990-07-30 1991-07-16 Hexa-n-(o-hydroxybenzyl) neomycine b destinee a l'inhibition des retrovirus humains et au traitement du sida

Country Status (5)

Country Link
EP (1) EP0541597A1 (fr)
JP (1) JPH05509306A (fr)
AU (1) AU640511B2 (fr)
CA (1) CA2085367A1 (fr)
WO (1) WO1992002530A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009792A1 (fr) * 1992-10-23 1994-05-11 University Of Massachusetts Medical Center Inhibition de la fixation arn/ligand au moyen de petites molecules
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
EP1385540A2 (fr) * 2001-05-10 2004-02-04 Wyeth Composition et methode permettant d'augmenter la densite cellulaire dans des cultures cellulaires infectees par un lentivirus
WO2005041984A1 (fr) * 2003-10-31 2005-05-12 Steele Philip M Compositions et traitements destines a des infections par un virus enveloppe
WO2007028012A2 (fr) * 2005-09-01 2007-03-08 Isis Pharmaceuticals, Inc. Analogues d'aminoglycosides 4,5-substitues 6'-modifies antibacteriens
US7893039B2 (en) 2005-12-02 2011-02-22 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US7943749B2 (en) 2004-11-05 2011-05-17 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
US8318685B2 (en) 2010-11-17 2012-11-27 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8367625B2 (en) 2008-10-09 2013-02-05 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8372813B2 (en) 2008-10-09 2013-02-12 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8377896B2 (en) 2008-09-10 2013-02-19 Isis Pharmaceuticals, Inc Antibacterial 4,6-substituted 6′, 6″ and 1 modified aminoglycoside analogs
US8399419B2 (en) 2008-09-10 2013-03-19 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8481502B2 (en) 2009-10-09 2013-07-09 Achaogen, Inc. Antibacterial aminoglycoside analogs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Antibiotics, vol. 26, no. 10, 1973, W.T. Shier et al.:" Chemistry and biochemistry of the neomycins. XVI synthesis and bioactivity of hexa-n-benzylneomycins", pages 547-550, see the whole article *
The Journal of Antibiotics, vol. XLII, no. 1, 1989, Y. Take et al.:" Comparative studies of the inhibitory properties of antibiotics on human immunodeficiency virus and avian myeloblastosis virus reverse transcriptases and cellular DNA polymerases", pages 107-115, see the whole article, especially page 110, table 1 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009792A1 (fr) * 1992-10-23 1994-05-11 University Of Massachusetts Medical Center Inhibition de la fixation arn/ligand au moyen de petites molecules
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
EP2298343A1 (fr) * 2001-05-10 2011-03-23 Wyeth LLC Composition et methode permettant d'augmenter la densite cellulaire dans des cultures cellulaires infectees par un lentivirus
EP1385540A2 (fr) * 2001-05-10 2004-02-04 Wyeth Composition et methode permettant d'augmenter la densite cellulaire dans des cultures cellulaires infectees par un lentivirus
EP1385540A4 (fr) * 2001-05-10 2004-12-01 Wyeth Corp Composition et methode permettant d'augmenter la densite cellulaire dans des cultures cellulaires infectees par un lentivirus
US7160721B2 (en) 2001-05-10 2007-01-09 Wyeth Composition and method for increasing cell density in cell cultures infected with lentivirus
WO2005041984A1 (fr) * 2003-10-31 2005-05-12 Steele Philip M Compositions et traitements destines a des infections par un virus enveloppe
US7943749B2 (en) 2004-11-05 2011-05-17 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
WO2007028012A3 (fr) * 2005-09-01 2007-06-21 Isis Pharmaceuticals Inc Analogues d'aminoglycosides 4,5-substitues 6'-modifies antibacteriens
WO2007028012A2 (fr) * 2005-09-01 2007-03-08 Isis Pharmaceuticals, Inc. Analogues d'aminoglycosides 4,5-substitues 6'-modifies antibacteriens
US8114856B2 (en) 2005-12-02 2012-02-14 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8569264B2 (en) 2005-12-02 2013-10-29 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US7893039B2 (en) 2005-12-02 2011-02-22 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8399419B2 (en) 2008-09-10 2013-03-19 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8742078B2 (en) 2008-09-10 2014-06-03 Isis Pharmaceuticals, Inc. Antibacterial 4,6-substituted 6′, 6″ and 1 modified aminoglycoside analogs
US8377896B2 (en) 2008-09-10 2013-02-19 Isis Pharmaceuticals, Inc Antibacterial 4,6-substituted 6′, 6″ and 1 modified aminoglycoside analogs
US8372813B2 (en) 2008-10-09 2013-02-12 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8367625B2 (en) 2008-10-09 2013-02-05 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8481502B2 (en) 2009-10-09 2013-07-09 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8653041B2 (en) 2010-11-17 2014-02-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
US8318685B2 (en) 2010-11-17 2012-11-27 Achaogen, Inc. Antibacterial aminoglycoside analogs

Also Published As

Publication number Publication date
JPH05509306A (ja) 1993-12-22
AU8230091A (en) 1992-03-02
AU640511B2 (en) 1993-08-26
EP0541597A1 (fr) 1993-05-19
CA2085367A1 (fr) 1992-01-31

Similar Documents

Publication Publication Date Title
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
WO1989007939A2 (fr) Coumarines permettant d'inhiber la transcriptase inverse chez les etres humains
JPH0649652B2 (ja) ３’―アジド―２’，３’―ジデオキシウリジン抗レトロウィルス組成物
WO1992002530A1 (fr) Hexa-n-(o-hydroxybenzyl) neomycine b destinee a l'inhibition des retrovirus humains et au traitement du sida
US20160289257A1 (en) Glycomimetic compounds and methods to inhibit infection by hiv
JP3237836B2 (ja) 抗ウイルス医薬組成物
TURANO et al. Inhibitory effect of papaverine on HIV replication in vitro
US6150414A (en) Compositions and methods for treating viral infections
JPS63310819A (ja) 抗レトロウイルス活性をもつ糖タンパク処理抑制剤
US5026726A (en) Gossylic iminolactones and gossylic lactones and their anti-viral activities
KR20000069296A (ko) 항바이러스 활성을 갖는 살비아 종의 추출물
DE68914990T2 (de) Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo.
EP0290817B1 (fr) Utilisation d'oxétanocine pour inhiber HIV
EP0476391B1 (fr) Composition anti-SIDA contenant cépharanthine comme agent thérapeutique
JP2000186040A (ja) 抗ｈｉｖ感染症剤
DE4320597A1 (de) Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
AU3423989A (en) Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
EP1421942A1 (fr) Utilisation de la glyzyrrhizine et de ses dérivés comme inducteurs de RANTES
JPS63107924A (ja) 抗レトロウイルス剤
WO1989009055A1 (fr) Composition anti-virale contenant des diones polycycliques aromatiques et analogues de nucleoside, et procede de traitement d'infections retrovirales
WO1989007384A2 (fr) Composes a base d'iodure de 2-methylisoquinolinium utilises dans le traitement contre le sida
CA1306694C (fr) Preparation pharmaceutique et methode d'inhibition de la replication du virus htlv-iii (sida)
JPH07509442A (ja) ウィルス病処置でのホスホリル化フラボノイド類
IE20020449A1 (en) Anti-viral compounds
WO1989002741A2 (fr) Inhibiteurs de la transcriptase inverse de l'hiv servant au traitement du sida

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991913197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2085367

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991913197

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1991913197

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991913197

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载